Bioactive lysophospholipids and mesangial cell intracellular signaling pathways: Role in the pathobiology of kidney disease

Histology and Histopathology

Volumn 20, Issue 2, 2005, Pages 603-613

  Kamanna, Vaijinath S ^a,c   Bassa, B V ^a   Ganji, S H ^a   Roh, D D ^b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b Nephrology Associates Medical Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EDG receptors; EGF receptor; G protein coupled receptors; G2A; GPR4; Lysophosphatidic acid; Lysophosphatidylcholine; MAP kinase; Renal disease; Signal transduction; Sphingolipids

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR; GENISTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE C GAMMA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN C FOS; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAC PROTEIN; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SPHINGOSINE 1 PHOSPHATE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNINDEXED DRUG;

AUTOCRINE EFFECT; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CHEMOTAXIS; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GLOMERULOPATHY; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIPOGENESIS; MACROPHAGE ACTIVATION; MESANGIUM CELL; MOLECULAR CLONING; MONOCYTE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION;

ANIMALS; CELL PROLIFERATION; GLOMERULAR MESANGIUM; HUMANS; KIDNEY DISEASES; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MODELS, BIOLOGICAL; PHOSPHORYLCHOLINE; RECEPTORS, LYSOPHOSPHATIDIC ACID; RECEPTORS, LYSOPHOSPHOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

MAMMALIA;

EID: 16344375307     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. An S., Bleu T., Hallmark O.G. and Goetzl E.J. (1998). Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem .273, 7906-7910.
2. Anilker B. and Chun J. (2004). Lysophospholipid G protein-coupled receptors. J. Biol. Chem. 279, 20555-20558.
3. Balazs L., Okolicany J., Ferrebee M., Tolley B. and Tigyi G. (2001). Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am. J. Physiol. 280, R466-72.
4. Bandoh K., Aoki J., Hsono H., kobayashi T., Murakami K., Tsujimoto M., Aria H. and Inoue K. (1999). Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274, 27776-27785.
5. Bassa B.V., Roh D.D., Kirschenbaum M.A. and Kamanna V.S. (1998). Atherogenic lipoproteins stimulate mesangial cell p42 mitogen-activated protein kinase. J. Am. Soc. Nephrol. 9, 488-496.
6. Bassa B.V., Roh D.D., Vaziri N.D., Kirschenbaum M.A. and Kamanna V.S. (1999). Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLC-1 and Tyrosine kinase-Ras pathways. Am. J. Physiol. 277, F328-F337.
7. Chai Y.C., Howe P.H., DiCorleto P.E. and Chisolm G.M. (1996). Oxidized low-density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells: evidence for release of FGF-2. J. Biol. Chem. 271, 17791-17797.
8. Cunnick J.M., Dorsey J.F., Standley T., Turkson J., Kraker A.J., Fry D.W., Jove R. and Wu J. (1998). Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway. J. Biol. Chem. 272, 14468-75.
9. Daub H., Weiss F.U., Wallasch C. and Ullrich A. (1996) Role of transactivation of the EGF receptor in signaling by G-protien-coupled receptors. Nature 379, 557-560.
10. Deshmukh G.D., Radin N.S., Gattone V.H. and Shayman J.A. (1994). Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse. J. Lipid Res. 35, 1611-1618.
11. de Vries B., Matthijsen R.A., van Bijnen A.A., Wolfs T.G. and Buurman W.A. (2003). Lysophosphatidic acid prevents renal ischemia-reperfusion injury b by inhibition of apoptosis and complement activation. Am. J. Pathol. 163, 47-56.
12. Diamond J.R. (1991). Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int. 39, S29-S34.
13. Eichholtz T., Jalink K., Fahrenfort I. and Moolenaar W.H. (1993). The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291, 677-680.
14. Fang X., Schummer M., Mao M., Yu S., Tabassam F.H., Swaby R., Hasegawa Y., Tanyi J.L., LaPushin R., Eder A., Jaffe R., Erickson J. and Mills G.B. (2002). Lysophoaphaatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta 1582, 257-264.
15. Fourcade O., Simon M.F., Viode C., Rugani N., Leballe F., Ragab A., Fournie B., Sarda L. and Chap H. (1995). Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 80, 919-927.
16. Fukushima N., Ishii I., Contos J.A. Weiner J.A. and Chun J. (2001) Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41, 507-534.
17. Gennero I., Fauvel J., Nieto M., Cariven C., Gaits F., Briand-Mesange F., Chap H. and Salles J.P. (2002). Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolisis on mesangial cells cultured at low density. J. Biol. Chem. 277, 12724-12734.
18. Grewal J.S., Luttrell L.M. and Raymond J.R. (2001). G protein-coupled receptors desensitize and down-regulate epidermal growth factor receptors in renal mesangial cells. J. Biol. Chem. 276, 27335-27344.
19. Gschwind A., Prenzel N. and Ullrich A. (2002). Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res. 62, 6329-6336.
20. Hackel P.O., Zwick E., Prenzel N. and Ullrich A. (1999). Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11, 184-189.
21. Hanafusa N., Yatomi Y., Yamada K., Hori Y., Nangaku M., Oduda T., Fujita T., Kurokawa K. and Fukagawa M. (2002). Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol. Dial. Transplant. 17, 580-586.
22. Herrlich A., Daub H., Knebel A., Herrlich P., Ullrich A., Schultz G. and Gudermann T. (1998). Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc. Natl. Acad. Sci. USA 95, 8985-8990.
23. Hla T. and Maciag T.J. (1990). An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to g protein coupled receptors. J. Biol. Chem. 265, 9308-9313.
24. Holvoet P., Donck J., Landeloos M., Brovwers E., Luijtens K., Arnout J., Lesaffre E., Vanrenterghem Y. and Collen D. (1996). Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb. Haemost. 76, 663-669.
25. Hooks S.B., Santos W.L., Im D.S., Heise C.E., Macdonald T.L. and Lynch K.R. (2001). Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is EDG-receptor independent. J. Biol. Chem. 276, 4611-4621.
26. Huang M.C., Graeler M., Shankar G., Spencer J. and Goetzl E.J. (2002). Lysophospholipid mediators of immunity and neoplasia. Biochim. Biophys. Acta 1582, 161-167.
27. Huang Y.H., Schafer-Elinder L., Wu R., Claesson H.E. and Frostegard J. (1999). Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin. Exp. Immunol. 116, 326-331.
28. Iwata M., Herrington J. and Zager R.A. (1995). Sphingosine: a mediator of acute renal tubuloar inury and subsequent cytoresistance. Proc. Natl. Acad. Sci. USA 92, 8970-8974.
29. Im D.S., Heise C.E., Harding M.A., George S.R., O'Dowd B.F., Theodorescu D. and Iynch K.R. (2000). Molecular characterization of a lysophoaphatidic acid receptor, EDG-1, expressed in prostate. Mol. Pharmacol. 57, 753-759.
30. Inoue N. (2002). LPA as a determinant of mesangial growth and apoptosis. Semin. Nephrol. 5, 415-22.
31. 2+ and contractility in cultured rat mesangial cells. Cir. Res. 77, 888-896.
32. Inoue C.N., Epstein M., Forster H.G., Hotta O., Kondo Y. and Iinuma K. (1999). Lysophosphatidic acid and mesangial cells: Implications for renal diseases. Clin. Sci. (Lond) 96, 431-436.
33. Inoue C.N., Ko Y.H., Guggino W.B., Forster H.G. and Epstein M. (1997). Lysophosphatidic acid and platelet-derived growth factor synergistically stimulate growth of cultured rat mesangial cells. Proc. Soc. Exp. Biol. Med. 216, 370-379.
34. Ishi I., Contos J.J., Fukushima N. and Chun J. (2000). Functional comparisions of the lysophosphatidic acid receptors, LPA1/V2G-1/EDG-2, LPA2/EDG4, and LPA3/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol. Pharmacol. 58, 895-902.
35. Jing Q., Xin S.M., Zhang W.B., Wang P., Qin Y.W. and Pei G. (2000). Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Cir. Res. 87, 52-59.
36. Kabarowski J.H., Feramisco J.D., Le L.Q., Gu J.L., Luoh S.W., Simon M.I. and Witte O.N. (2000). Direct genetic demonstration of G alpha 13 coupling to the orphan G protein-coupled receptor G2A leading to RhoA-dependent rearrangement. Proc. Natl. Acad. Sci USA 97, 12109-12114.
37. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N. and Xu Y. (2001). Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293, 702-705.
38. Kamanna V.S., Pai R., Roh D.D. and Kirschenbaum M.A. (1996). Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation and proliferation. Lab. Invest. 74, 1067-1079.
39. Kamnna V.S., Bassa B.V. and Kirschenbaum M.A. (1997). Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Curr. Opin. Nephrol. Hyperten. 6, 205-211.
40. Kamanna V.S., Roh D.D. and Kirchenbaum M.A. (1998). Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus. Histol. Histopathol. 13, 169-179.
41. Kamanna V.S., Pai R., Ha H., Kirshcenbaum M.A. and Roh D.D. (1999a). Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int. 55, 2192-2202.
42. Kamanna V.S., Bassa B.V., and Vaziri N.D. and Roh D.D. (1999b). Atherogenic lipoproteins and tyrosine kinase mitogenic signaling in mesangial cells. Kidney Int. 56, S70-S75.
43. Katsuma S., Hada Y., Shiojima S., Hirasawa A., Tanoue A., Takagaki K., O Yano J. and Tsujimoto G. (2003). Transcriptional profiling of gene expression patterns during sphingosine 1-phosphate-induced mesangial cell proliferation. Biochem. Biophys. Res. Commun. 300, 577-84.
44. Kluk M.J. and Hla T. (2002). Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G protein-coupled receptors. Biochim. Biophys. Acta 1582, 72-80.
45. Kohno M., Yokokawa K., Yasunari K., Minami N., Kano H., Hanehira T. and Yoshikawa J. (1998). Induction of lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98, 353-359.
46. Kugiyama K., Ohgushi K., Ohgushi M., Sugiyama S., Murohara T., Fukunaga K., Miyamoto E. and Yasue H. (1992). Lysophosphotidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells bya pathway involving protein kinase C activation. Cir. Res. 71, 1422-1428.
47. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R. and Henry P.D. (1990). Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344, 160-162.
48. Kume N. and Gimbrone M.A. Jr (1994). Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human vascular endothelial cells. J Clin Invest 93, 907-911.
49. Kume N., Cybulsky M.I. and Gimbrone M.A. Jr (1992). Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90, 1138-1144.
50. Laffargue M., Raynal P., Yart A., Peres C., Wetzker R., Roche S., Payrastre B. and Chap H. (1999). An epidermal growth factor receptor/Gab1 signaling pathway is required for activation of phosphoinositide 3-kinase by lysophosphatidic acid. J. Biol. Chem. 274, 32835-32841.
51. Le L.Q., Kabarowski J.H., Weng Z., Satterthwaite A.B., Harvill E.T., Jensen E.R., Miller J.F. and Witte O.N. (2001). Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 14, 561-571.
52. Lee H.S. and Kim Y.S. (1998). Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int. 54, 848-856.
53. Lee H., Liao J., Graeler M., Huang Mei-Chuan. and Goetzl E.J. (2002). Lysophospholipid regulation of mononuclear phagocytes. Biochim. Biophys. Acta 1582, 175-177.
54. Leung S.W., Teoh H., Quan A. and Man R.Y. (1999). Endothelial dysfunction exacerbates the impairment of relaxation by lysophosphatidylcholine in porcine coronary artery. Clin. Exp. Pharmacol. Physiol. 24, 984-986.
55. Lin P. and Ye R.D., (2003). The lysophospholipid receptor G2A activates a specific combination of G proteins and promotes apoptosis. J. Biol. Chem. 278, 14379-14386.
56. Luttrell L.M., Della Rocca G.J., van Biesen T., Luttrell D.K. and Lefkowitz R.J. (1997). Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for tG protein-coupled receptor-mediated Ras activation. J. Biol. Chem. 272, 4637-4644.
57. Lynch K.R. (2002). Lysophospholipid receptor nomenclature. Biochim. Biophys. Acta 1582, 70-71.
58. Maggi E., Bellazi R., Gazo A., Seccina M. and Bellamo G. (1994). Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int. 46, 869-876.
59. Mizobata R. (2003). Effects of lysophosphatidylcholine on expression of monocyte chemoattractant protein-1 in glomerular endothelial cells. Nippon Jinzo Gakkai Shi. 45, 76-83.
60. Moolenaar W. H., Kranenburg O., Postma F.R. and Zondag G.C. (1997). Lysophosphatidic acid: G-protein signalling and cellular responses. Curr. Opin. Cell Biol. 9, 168-173.
61. Moolenaar W.H., van Meeteren L.A. and Giepmans B.N. (2004). The ins and outs of lysophosphatidic acid signaling. Bioessay 26, 870-881.
62. Nakano T., Raines E.W., Abraham J.A. Klagsburn M. and Ross R. (1994). Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth mRNA in human monocytes. Proc. Natl. Acad. Sci. USA 91, 1069-1073.
63. Ohgushi M. Kugiyama K., Fukunaga K., Murohara T., Sugiyama S., Miyamoto E. and Yasue H. (1993). Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arteriosc. Thromb. 13, 1525-1532.
64. Ono T., Kanatsu K., Doi T., Sekita K., Onoe C., Nagai H., Muso E., Yoshida H., Tamura T. and Kawai C. (1991). Relationship of intraglomerualar coagulation and platelet aggregation to glomerular sclerosis. Nephron 58, 429-36.
65. Ozaki H., Ishii K., Arai H., Kume N. and Kita T. (1999). Lysophosphatidyl-choline activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells. Atherosclerosis 143, 261-266.
66. Pages C., Daviaud D., An S., Krief S., Lafontan M., Valet P. and Saulnier-Blache J.S. (2001). Endothelial differentiation gene-2 receptor is involved in lysophosphatidic acid-dependent control of 3T3F442A preadipocyte proliferation and spreading. J. Biol. Chem. 276, 11599-11605.
67. Parthasarathy S. and Barnett J. (1990). Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc. Natl. Acad. Sci. USA 87, 9741-9745.
68. Pfeilschifter J., Schalkwijk C., Briner V.A. and van den Bosch H. (1993). Cytokine stimulated secretion of Group II phospholipase A2 by rat mesangial cells. J. Clin. Invest. 92, 2516-2523.
69. Quinn M.T., Parthasarathy S. and Steinberg D. (1988). Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherosclerosis. Proc. Natl. Acad. Sci. USA 85, 2805-2809.
70. Radu C.G., Yang L.V., Riedinger M., Au M. and Witte O.N. (2004). T cell Chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc. Natl. Acad. Sci. USA 101, 245-250.
71. Rikitake Y., Hirata K., Yamashita T., Iwai K., Kobayashi S., Itoh H., Ozakai M., Ejiri J., Shiomi M., Inoue N., Kawashima S. and Yokoyama M. (2002). Expression of G2A, a receptor for lysophosphatidlycholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 22, 2049-2053.
72. Roh D.D., Kamanna V.S. and Kirschenbaum M.A. (1998a). Oxidative modification of low density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins. Am. J. Nephrol. 18, 344-350.
73. Roh D.D., Kamanna V.S. Kirschenbaum M.A. (1998b). Atherogenic lipoproteins enhance murine cortical epithelial cell fibronectin protein synthesis and gene expression. Am. J. Nephrol. 18, 83-88.
74. Rother E., Brandl R., Baker D.L., Goyal P., Gebhard H., Tigyi G. and Siess W. (2003). Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by lipid core of atherosclerotic plaques. Circulation 108, 741-747.
75. Sasagawa T., Suzuki K., Shiota T., Kondo T. and Okita M. (1998). The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J. Nutr. Sci. Vitaminol. (Tokyo) 44, 809-818.
76. Siess W., Zangl K.J., Essler M., Bauer M., Brandl R., Cominty C., Bittman R., Tigyi G. and Aepfelbacher M. (1999). Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 96, 6931-6936.
77. Spiegel S. and Milstein S. (1995) Sphingolipid metabolites: members of a new class of lipid second messengers. J. Membr. Biol. 46, 225-237.
78. Spiegel S. and Milstien S. (2003). Sphingosine-1-phosphate: an enigmatic signaling lipid. Nat. Rev. Mol. Cell Biol. 4, 397-407.
79. Sugiyama S., Kugiyama K., Ohgushi M., Fujimoto K. and Hirofumi Y. (1994). Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Circ. Res. 74, 565-575.
80. Takahashi M., Okazki H., Ogata Y., Takeuchi K., Ikeda V. and Shimada K. (2002). Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen- activated protein kinase-dependent mechanism. Atherosclerosis 161, 387-394.
81. Thumser A.E., Voysey J.E. and Wilton D.C. (1994). The binding of lysophospholipids to rat liver fatty acid-binding protein and albumin. Biochem. J. 301, 801-806.
82. Tigyi G and Miledi R. (1992) Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in Pc12 pheochromocytoma cells. J. Biol. Chem. 267, 2136-21367.
83. Tone Y., Yukawa S., Varghese Z. and Moorhead J.F. (1999). Lysophosphatidylcholine induces platelet-derived growth factor expression in a human mesangial cell line. Kidney Int. Suppl. 71, S182-S185.
84. Tselepis A.D. and John Chapman M. (2002). Inflammation, bioactive lipids, and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 3, 57-68.
85. van Corven E.J., Groenink A., Jalink K., Eichholtz T. and Moolenaar, W.H. (1989). Lysophosphadate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59, 45-54.
86. Van Tits L., De Graaf J., Hak-Lemmers H., Bredie S., Demacker P., Holvo Stalenhoef A. (2003). Increased levels of low-density lipoprotein oxidation in patients familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab. Invest. 83, 13-21.
87. Vuong T.D., Stroes E.S., Willekes-Koolschijn N., Rabelink T.J., Koomans H.A. and Joles J.A. (1999). Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects. Kidney Int. 55. 1005-1010.
88. Wada A., Sugiura T., Arai M., Tojio H., Okamoto M., Fujiwara Y., Ueda N. and Kamada T. (1995). Group II phospholipase AII promotes mesangial cell proliferation via phospholipids. J. Am. Soc. Nephrol. 5, 704A.
89. Wada A., Tojo H., Sugiura T., Fujiwara Y., Kamada T., Ueda N. and Okamoto M. (1997). Group II phospholipase A2 as an autocrine growth factor mediating interleukin-1 action on mesangial cells. Biochim. Biophys. Acta 1345, 99-108.
90. Watanabe M. and Okada T. (2003). Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart. Mol. Cell Biochem. 248, 209-215.
91. Watanabe T., Pakala R., Koba S., Katagiri T. and Benedict C.R. (2001). Lysophosphatidylcholine and reactive oxygen species mediate the synergistic effect of mildly oxidized LDL with serotonin on vascular smooth muscle cell proliferation. Circulation 103, 1440-1445.
92. Weng Z., Fluckiger A.C., Nisitani S., Wahl M.I., Le L.Q., Hunter C.A., Fernal A.A., Le Beau M.M. and Witte O.N. (1998). A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc. Natl. Acad. Sci. USA 95, 12334-12339.
93. Wu J. and Cunnick J.M. (2002) Trans-regulation of epidermal growth factor receptor by lysophosphatidic acid and G protein-coupled receptors. Biochim. Biophys. Acta 1582, 100-106.
94. Xing Y., Ganji S.H., Noh J.W. and Kamanna V.S. (2004). Cell density-dependent expression of EDG family receptors and mesangial cell proliferation: Role in lysophosphatidic acid-mediated cell growth. Am. J. Physiol. Renal Physiol.
95. Xu Y.J., Aziz O.A., Bhugra P., Arneja A.S., Mendis M.R. and Dhalla N.S. (2003). Potential role of lysophosphatidic acid in hypertension and atherosclerosis. Can. J. Cardiol. 13, 1525-36.
96. 2+ control lysophosphatidate signaling through EDG-2 receptor. J. Biol. Chem. 275, 27520-27530.
97. Yamakawa T., Tanaka S., Numaguchi K., Motley E.D., Inagami T. and Eguchi S. (2002). Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 22, 752-758.
98. Yokomori H., Yoshimura K., Funakoshi S., Nagai T., Fujimaki K., Nomur M., Ishii H. and Oda M. (2004). Rho modulates hepatic sinusoidal endothelial fenestrae via regulation of the actin cytoskeleton in rat endothelial cells. Lab. Invest. 84, 857-864.
99. Zager R.A., Iwata M., Conrad D.S., Burkhart K.M. and Igarashi Y. (1997). Altered ceramide and sphingosine expression during the induction phase of ischemic acute renal failure. Kidney Int. 52, 60-70.
100. Zager R.A., Conrad S., Lochhead K., Sweeney E.A., Igarashi Y. and Burkhart K.M. (1998). Altered sphingomyelinase and ceramide expression in the setting of ischemic and nephrotoxic acute renal failure. Kidney Int. 53, 573-82.
101. Zhu K., Baudhuin I.M., Hong G., Williams F.S., Cristina K.L., Kabarowski J.H., Witte O.N. and Xu Y. (2001). Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J.. Biol. Chem. 276, 41325-41335.
102. Zohn I.E., Klinger M., Karp X., Kirk H., Symons M., Chrzanowska-Wodnicka. M., Der C.J. and Kay R.J. (2000). G2A is an oncogenic G protein-coupled receptor. Oncogene 19, 3866-3877.